Do analysts prefer BMK or AZN?

AstraZeneca has a consensus target price of £153, indicating a potential upside of 21.12%. Given AstraZeneca's stronger consensus rating and higher possible upside, analysts plainly believe AstraZeneca is more favorable than Benchmark. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Benchmark 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 AstraZeneca 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.67

Which has better earnings & valuation, BMK or AZN?

AstraZeneca has higher revenue and earnings than Benchmark. AstraZeneca is trading at a lower price-to-earnings ratio than Benchmark, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Benchmark £79.16M 1,189.43 -£39.55M £0.06 246,774.19 AstraZeneca £61.37B 3.19 £8.71B £664.00 19.02

Is BMK or AZN more profitable?

AstraZeneca has a net margin of 17.02% compared to Benchmark's net margin of -43.67%. AstraZeneca's return on equity of 21.68% beat Benchmark's return on equity. Company Net Margins Return on Equity Return on Assets Benchmark -43.67% -15.96% -1.07% AstraZeneca 17.02% 21.68% 7.68%

Which has stronger earnings and valuation, GSK or AZN?

AstraZeneca has higher revenue and earnings than GSK. GSK is trading at a lower price-to-earnings ratio than AstraZeneca, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GSK £33.20B 2.33 £2.50B £142.10 13.59 AstraZeneca £61.37B 3.19 £8.71B £664.00 19.02

Is GSK or AZN more profitable?

AstraZeneca has a net margin of 17.02% compared to GSK's net margin of 14.52%. GSK's return on equity of 28.35% beat AstraZeneca's return on equity. Company Net Margins Return on Equity Return on Assets GSK 14.52% 28.35% 9.56% AstraZeneca 17.02% 21.68% 7.68%

Does the media favor GSK or AZN?

In the previous week, GSK and GSK both had 17 articles in the media. GSK's average media sentiment score of 0.27 beat AstraZeneca's score of 0.13 indicating that GSK is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GSK 2 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral AstraZeneca 3 Very Positive mention(s) 0 Positive mention(s) 8 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral

Do analysts prefer AZN or DPH?

AstraZeneca presently has a consensus target price of £153, suggesting a potential upside of 21.12%. Given AstraZeneca's stronger consensus rating and higher probable upside, analysts clearly believe AstraZeneca is more favorable than Dechra Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AstraZeneca 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.67 Dechra Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Does the media prefer AZN or HIK?

In the previous week, AstraZeneca had 16 more articles in the media than Hikma Pharmaceuticals. MarketBeat recorded 17 mentions for AstraZeneca and 1 mentions for Hikma Pharmaceuticals. AstraZeneca's average media sentiment score of 0.13 beat Hikma Pharmaceuticals' score of 0.00 indicating that AstraZeneca is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AstraZeneca 3 Very Positive mention(s) 0 Positive mention(s) 8 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral Hikma Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate AZN or INDV?

AstraZeneca presently has a consensus target price of £153, suggesting a potential upside of 21.12%. Given AstraZeneca's stronger consensus rating and higher possible upside, equities analysts clearly believe AstraZeneca is more favorable than Indivior. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AstraZeneca 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.67 Indivior 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better earnings and valuation, AZN or INDV?

AstraZeneca has higher revenue and earnings than Indivior. Indivior is trading at a lower price-to-earnings ratio than AstraZeneca, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AstraZeneca £61.37B 3.19 £8.71B £664.00 19.02 Indivior £1.40B 1.38 -£2.36M -£1.21 N/A

Is AZN or INDV more profitable?

AstraZeneca has a net margin of 17.02% compared to Indivior's net margin of 11.44%. AstraZeneca's return on equity of 21.68% beat Indivior's return on equity. Company Net Margins Return on Equity Return on Assets AstraZeneca 17.02% 21.68% 7.68% Indivior 11.44% -23.90% 2.37%

Does the media prefer AZN or INDV?

In the previous week, AstraZeneca had 16 more articles in the media than Indivior. MarketBeat recorded 17 mentions for AstraZeneca and 1 mentions for Indivior. Indivior's average media sentiment score of 0.67 beat AstraZeneca's score of 0.13 indicating that Indivior is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AstraZeneca 3 Very Positive mention(s) 0 Positive mention(s) 8 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral Indivior 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

AstraZeneca (AZN) Competitors

£126.32 0.00 (0.00%)

As of 07/31/2026 12:10 PM Eastern

Compare

AZN vs. BMK, GSK, DPH, HIK, and INDV

Should you buy AstraZeneca stock or one of its competitors? MarketBeat compares AstraZeneca with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with AstraZeneca include Benchmark (BMK), GSK (GSK), Dechra Pharmaceuticals (DPH), Hikma Pharmaceuticals (HIK), and Indivior (INDV). These companies are all part of the "pharmaceuticals" industry.

How does AstraZeneca compare to Benchmark?

Benchmark (LON:BMK) and AstraZeneca (LON:AZN) are both large-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

AstraZeneca has a net margin of 17.02% compared to Benchmark's net margin of -43.67%. AstraZeneca's return on equity of 21.68% beat Benchmark's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Benchmark	-43.67%	-15.96%	-1.07%
AstraZeneca	17.02%	21.68%	7.68%

13.3% of Benchmark shares are held by institutional investors. Comparatively, 67.8% of AstraZeneca shares are held by institutional investors. 63.7% of Benchmark shares are held by insiders. Comparatively, 0.2% of AstraZeneca shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Benchmark has a beta of 0.69, indicating that its stock price is 31% less volatile than the broader market. Comparatively, AstraZeneca has a beta of 0.225, indicating that its stock price is 78% less volatile than the broader market.

AstraZeneca has higher revenue and earnings than Benchmark. AstraZeneca is trading at a lower price-to-earnings ratio than Benchmark, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Benchmark	£79.16M	1,189.43	-£39.55M	£0.06	246,774.19
AstraZeneca	£61.37B	3.19	£8.71B	£664.00	19.02

In the previous week, AstraZeneca had 17 more articles in the media than Benchmark. MarketBeat recorded 17 mentions for AstraZeneca and 0 mentions for Benchmark. AstraZeneca's average media sentiment score of 0.13 beat Benchmark's score of 0.00 indicating that AstraZeneca is being referred to more favorably in the news media.

Company	Overall Sentiment
Benchmark	Neutral
AstraZeneca	Neutral

AstraZeneca has a consensus target price of £153, indicating a potential upside of 21.12%. Given AstraZeneca's stronger consensus rating and higher possible upside, analysts plainly believe AstraZeneca is more favorable than Benchmark.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Benchmark	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
AstraZeneca	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

AstraZeneca beats Benchmark on 12 of the 16 factors compared between the two stocks.

How does AstraZeneca compare to GSK?

GSK (LON:GSK) and AstraZeneca (LON:AZN) are both large-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, institutional ownership, earnings, media sentiment, valuation, risk and analyst recommendations.

GSK pays an annual dividend of GBX 66 per share and has a dividend yield of 3.4%. AstraZeneca pays an annual dividend of GBX 316.71 per share and has a dividend yield of 2.5%. GSK pays out 46.4% of its earnings in the form of a dividend. AstraZeneca pays out 47.7% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. GSK is clearly the better dividend stock, given its higher yield and lower payout ratio.

AstraZeneca has a net margin of 17.02% compared to GSK's net margin of 14.52%. GSK's return on equity of 28.35% beat AstraZeneca's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GSK	14.52%	28.35%	9.56%
AstraZeneca	17.02%	21.68%	7.68%

AstraZeneca has higher revenue and earnings than GSK. GSK is trading at a lower price-to-earnings ratio than AstraZeneca, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GSK	£33.20B	2.33	£2.50B	£142.10	13.59
AstraZeneca	£61.37B	3.19	£8.71B	£664.00	19.02

GSK has a beta of 0.3, indicating that its share price is 70% less volatile than the broader market. Comparatively, AstraZeneca has a beta of 0.225, indicating that its share price is 78% less volatile than the broader market.

GSK currently has a consensus price target of GBX 2,041.43, suggesting a potential upside of 5.69%. AstraZeneca has a consensus price target of £153, suggesting a potential upside of 21.12%. Given AstraZeneca's stronger consensus rating and higher possible upside, analysts clearly believe AstraZeneca is more favorable than GSK.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GSK	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14
AstraZeneca	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

56.9% of GSK shares are held by institutional investors. Comparatively, 67.8% of AstraZeneca shares are held by institutional investors. 0.2% of GSK shares are held by company insiders. Comparatively, 0.2% of AstraZeneca shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, GSK and GSK both had 17 articles in the media. GSK's average media sentiment score of 0.27 beat AstraZeneca's score of 0.13 indicating that GSK is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GSK	2 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
AstraZeneca	3 Very Positive mention(s)	0 Positive mention(s)	8 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

AstraZeneca beats GSK on 10 of the 17 factors compared between the two stocks.

How does AstraZeneca compare to Dechra Pharmaceuticals?

AstraZeneca (LON:AZN) and Dechra Pharmaceuticals (LON:DPH) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, profitability, institutional ownership, earnings, risk, valuation, analyst recommendations and dividends.

AstraZeneca has higher revenue and earnings than Dechra Pharmaceuticals. Dechra Pharmaceuticals is trading at a lower price-to-earnings ratio than AstraZeneca, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AstraZeneca	£61.37B	3.19	£8.71B	£664.00	19.02
Dechra Pharmaceuticals	£761.50M	0.00	-£27.90M	-£0.25	N/A

In the previous week, AstraZeneca had 17 more articles in the media than Dechra Pharmaceuticals. MarketBeat recorded 17 mentions for AstraZeneca and 0 mentions for Dechra Pharmaceuticals. AstraZeneca's average media sentiment score of 0.13 beat Dechra Pharmaceuticals' score of 0.00 indicating that AstraZeneca is being referred to more favorably in the media.

Company	Overall Sentiment
AstraZeneca	Neutral
Dechra Pharmaceuticals	Neutral

67.8% of AstraZeneca shares are owned by institutional investors. Comparatively, 105.5% of Dechra Pharmaceuticals shares are owned by institutional investors. 0.2% of AstraZeneca shares are owned by insiders. Comparatively, 9.3% of Dechra Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

AstraZeneca pays an annual dividend of GBX 316.71 per share and has a dividend yield of 2.5%. Dechra Pharmaceuticals pays an annual dividend of GBX 45 per share. AstraZeneca pays out 47.7% of its earnings in the form of a dividend. Dechra Pharmaceuticals pays out -18,000.0% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

AstraZeneca has a beta of 0.225, indicating that its share price is 78% less volatile than the broader market. Comparatively, Dechra Pharmaceuticals has a beta of 0.78, indicating that its share price is 22% less volatile than the broader market.

AstraZeneca presently has a consensus target price of £153, suggesting a potential upside of 21.12%. Given AstraZeneca's stronger consensus rating and higher probable upside, analysts clearly believe AstraZeneca is more favorable than Dechra Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AstraZeneca	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Dechra Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

AstraZeneca has a net margin of 17.02% compared to Dechra Pharmaceuticals' net margin of -3.66%. AstraZeneca's return on equity of 21.68% beat Dechra Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AstraZeneca	17.02%	21.68%	7.68%
Dechra Pharmaceuticals	-3.66%	-3.92%	0.75%

Summary

AstraZeneca beats Dechra Pharmaceuticals on 13 of the 17 factors compared between the two stocks.

How does AstraZeneca compare to Hikma Pharmaceuticals?

AstraZeneca (LON:AZN) and Hikma Pharmaceuticals (LON:HIK) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, valuation, risk, media sentiment and profitability.

67.8% of AstraZeneca shares are held by institutional investors. Comparatively, 63.6% of Hikma Pharmaceuticals shares are held by institutional investors. 0.2% of AstraZeneca shares are held by insiders. Comparatively, 21.9% of Hikma Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

AstraZeneca has a net margin of 17.02% compared to Hikma Pharmaceuticals' net margin of 12.00%. AstraZeneca's return on equity of 21.68% beat Hikma Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AstraZeneca	17.02%	21.68%	7.68%
Hikma Pharmaceuticals	12.00%	15.83%	9.40%

AstraZeneca has a beta of 0.225, suggesting that its stock price is 78% less volatile than the broader market. Comparatively, Hikma Pharmaceuticals has a beta of 0.654, suggesting that its stock price is 35% less volatile than the broader market.

AstraZeneca has higher revenue and earnings than Hikma Pharmaceuticals. Hikma Pharmaceuticals is trading at a lower price-to-earnings ratio than AstraZeneca, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AstraZeneca	£61.37B	3.19	£8.71B	£664.00	19.02
Hikma Pharmaceuticals	£3.35B	1.00	£353.21M	£181.00	8.76

AstraZeneca pays an annual dividend of GBX 316.71 per share and has a dividend yield of 2.5%. Hikma Pharmaceuticals pays an annual dividend of GBX 84.14 per share and has a dividend yield of 5.3%. AstraZeneca pays out 47.7% of its earnings in the form of a dividend. Hikma Pharmaceuticals pays out 46.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Hikma Pharmaceuticals is clearly the better dividend stock, given its higher yield and lower payout ratio.

In the previous week, AstraZeneca had 16 more articles in the media than Hikma Pharmaceuticals. MarketBeat recorded 17 mentions for AstraZeneca and 1 mentions for Hikma Pharmaceuticals. AstraZeneca's average media sentiment score of 0.13 beat Hikma Pharmaceuticals' score of 0.00 indicating that AstraZeneca is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AstraZeneca	3 Very Positive mention(s)	0 Positive mention(s)	8 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral
Hikma Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

AstraZeneca presently has a consensus price target of £153, suggesting a potential upside of 21.12%. Hikma Pharmaceuticals has a consensus price target of GBX 1,687, suggesting a potential upside of 6.44%. Given AstraZeneca's higher possible upside, equities analysts clearly believe AstraZeneca is more favorable than Hikma Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AstraZeneca	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Hikma Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

AstraZeneca beats Hikma Pharmaceuticals on 11 of the 18 factors compared between the two stocks.

How does AstraZeneca compare to Indivior?

AstraZeneca (LON:AZN) and Indivior (LON:INDV) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, dividends, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations.

67.8% of AstraZeneca shares are owned by institutional investors. Comparatively, 86.0% of Indivior shares are owned by institutional investors. 0.2% of AstraZeneca shares are owned by insiders. Comparatively, 3.4% of Indivior shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, AstraZeneca had 16 more articles in the media than Indivior. MarketBeat recorded 17 mentions for AstraZeneca and 1 mentions for Indivior. Indivior's average media sentiment score of 0.67 beat AstraZeneca's score of 0.13 indicating that Indivior is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AstraZeneca	3 Very Positive mention(s)	0 Positive mention(s)	8 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral
Indivior	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

AstraZeneca presently has a consensus target price of £153, suggesting a potential upside of 21.12%. Given AstraZeneca's stronger consensus rating and higher possible upside, equities analysts clearly believe AstraZeneca is more favorable than Indivior.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AstraZeneca	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Indivior	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

AstraZeneca has higher revenue and earnings than Indivior. Indivior is trading at a lower price-to-earnings ratio than AstraZeneca, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AstraZeneca	£61.37B	3.19	£8.71B	£664.00	19.02
Indivior	£1.40B	1.38	-£2.36M	-£1.21	N/A

AstraZeneca has a net margin of 17.02% compared to Indivior's net margin of 11.44%. AstraZeneca's return on equity of 21.68% beat Indivior's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AstraZeneca	17.02%	21.68%	7.68%
Indivior	11.44%	-23.90%	2.37%

AstraZeneca has a beta of 0.225, suggesting that its stock price is 78% less volatile than the broader market. Comparatively, Indivior has a beta of 0.19, suggesting that its stock price is 81% less volatile than the broader market.

AstraZeneca pays an annual dividend of GBX 316.71 per share and has a dividend yield of 2.5%. Indivior pays an annual dividend of GBX 15 per share and has a dividend yield of 1.2%. AstraZeneca pays out 47.7% of its earnings in the form of a dividend. Indivior pays out -1,243.7% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Summary

AstraZeneca beats Indivior on 14 of the 18 factors compared between the two stocks.

Get AstraZeneca News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AZN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AZN vs. The Competition

Export

Metric	AstraZeneca	Pharmaceuticals Industry	Healthcare Sector	LON Exchange
Market Cap	£195.91B	£11.74B	£6.86B	£2.82B
Dividend Yield	1.88%	2.73%	2.59%	6.15%
P/E Ratio	19.02	799.05	282.27	368.29
Price / Sales	3.19	749.34	590.91	83,501.30
Price / Cash	38.89	14.82	28.60	27.89
Price / Book	4.80	10.39	10.93	7.04
Net Income	£8.71B	£2.82B	£3.49B	£5.89B
7 Day Performance	-1.99%	-0.18%	-0.64%	6.05%
1 Month Performance	-12.62%	-4.04%	-3.78%	-0.22%
1 Year Performance	13.76%	156.15%	61.99%	63.72%

AstraZeneca Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AZN AstraZeneca	4.1494 of 5 stars	£126.32 0.0%	£153 +21.1%	+13.8%	£195.91B	£61.37B	19.02	83,500
BMK Benchmark	N/A	£153 -0.6%	N/A	+63,123.1%	£94.15B	£79.16M	246,774.19	823
GSK GSK	2.4537 of 5 stars	GBX 1,931.50 -0.4%	GBX 2,041.43 +5.7%	+38.3%	£77.37B	£32.78B	13.59	70,212	Earnings Report
DPH Dechra Pharmaceuticals	N/A	N/A	N/A	N/A	£4.40B	£761.50M	N/A	2,457
HIK Hikma Pharmaceuticals	1.9174 of 5 stars	GBX 1,585 -0.6%	GBX 1,687 +6.4%	-18.0%	£3.34B	£3.35B	8.76	9,100

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:AZN) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

AstraZeneca (AZN) Competitors

AZN vs. BMK, GSK, DPH, HIK, and INDV

How does AstraZeneca compare to Benchmark?

Summary

How does AstraZeneca compare to GSK?

Summary

How does AstraZeneca compare to Dechra Pharmaceuticals?

Summary

How does AstraZeneca compare to Hikma Pharmaceuticals?

Summary

How does AstraZeneca compare to Indivior?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AZN vs. The Competition

AstraZeneca Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

AstraZeneca (AZN) Competitors

AZN vs. BMK, GSK, DPH, HIK, and INDV

How does AstraZeneca compare to Benchmark?

Is BMK or AZN more profitable?

Do institutionals and insiders hold more shares of BMK or AZN?

Which has more risk & volatility, BMK or AZN?

Which has better earnings & valuation, BMK or AZN?

Does the media prefer BMK or AZN?

Do analysts prefer BMK or AZN?

Summary

How does AstraZeneca compare to GSK?

Is GSK or AZN a better dividend stock?

Is GSK or AZN more profitable?

Which has stronger earnings and valuation, GSK or AZN?

Which has more volatility & risk, GSK or AZN?

Do analysts prefer GSK or AZN?

Do institutionals & insiders hold more shares of GSK or AZN?

Does the media favor GSK or AZN?

Summary

How does AstraZeneca compare to Dechra Pharmaceuticals?

Which has preferable valuation & earnings, AZN or DPH?

Does the media favor AZN or DPH?

Do insiders & institutionals have more ownership in AZN or DPH?

Is AZN or DPH a better dividend stock?

Which has more volatility & risk, AZN or DPH?

Do analysts prefer AZN or DPH?

Is AZN or DPH more profitable?

Summary

How does AstraZeneca compare to Hikma Pharmaceuticals?

Do insiders & institutionals have more ownership in AZN or HIK?

Is AZN or HIK more profitable?

Which has more volatility and risk, AZN or HIK?

Which has preferable valuation and earnings, AZN or HIK?

Is AZN or HIK a better dividend stock?

Does the media prefer AZN or HIK?

Do analysts recommend AZN or HIK?

Summary

How does AstraZeneca compare to Indivior?

Do insiders and institutionals hold more shares of AZN or INDV?

Does the media prefer AZN or INDV?

Do analysts rate AZN or INDV?

Which has better earnings and valuation, AZN or INDV?

Is AZN or INDV more profitable?

Which has more risk and volatility, AZN or INDV?

Is AZN or INDV a better dividend stock?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AZN vs. The Competition

AstraZeneca Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools